The Prader–Willi syndrome market is experiencing growth due to increasing in diagnosis rate owing to an increase in genetic testing, more and more identification of other lesser-known genetic ...

DelveInsight’s "Prader–Willi Syndrome Market Insights, Epidemiology, and Market Forecast – 2034" report delivers an in-depth understanding of PWS, historical and forecasted epidemiology as ...

This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for the Prader-Willi syndrome communityREDWOOD CITY, Calif., May 15, 2024 (GLOBE ...

About PWS Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15. The Prader-Willi Syndrome Association USA ...

Prader-Willi syndrome, which strikes only 1 in 15,000 people, can cause learning issues, muscles weakness, a slow metabolism and an insatiable appetite.

About Soleno Therapeutics, Inc. Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's first commercial product, VYKAT™ XR ...

MONTREAL — Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced the U.S. Food and Drug Administration (FDA) granted a Rare Pediatric Disease (RPD) ...

Quiver AI Summary Soleno Therapeutics, Inc. announced its participation in the 2025 United In Hope: International Prader-Willi Syndrome Conference, scheduled for June 24-28, 2025, in Phoenix, AZ.